AMG 747

Drug Profile

AMG 747

Alternative Names: AMG747

Latest Information Update: 01 May 2014

Price : $50

At a glance

  • Originator Amgen
  • Class Acetic acids; Antipsychotics; Fluorobenzenes; Piperazines; Small molecules
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 17 Feb 2014 Discontinued - Phase-II for Schizophrenia in Australia, Canada, Czech Republic, France, Malaysia, New Zealand, Poland, Russia, Singapore, Spain, United Kingdom and USA (PO) prior to February 2014
  • 14 Jun 2013 Amgen terminates two phase II trials in Schizoprenia in the USA, Australia, Canada, Czech Republic, France, Malaysia, New Zealand, Poland, Russian, Singapore, Spain and the United Kingdom (NCT01568229; NCT01568216)
  • 09 May 2013 Phase-II clinical trials in Schizophrenia in United Kingdom, Singapore, Malaysia, Russia, Poland, Spain, France, Czech Republic (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top